JB Chemicals & Pharmaceuticals Limited — Updates, 04-02-2025: Press Release

JB Chemicals & Pharmaceuticals (JB Pharma) reported a strong performance for Q3 FY25, with revenue of INR 963 crore, marking a 14% increase year-on-year from INR 845 crore in Q3 FY24. Net profit surged by 22% to INR 162 crore compared to INR 134 crore in the previous year. The operating EBITDA rose 15% to INR 270 crore, reflecting improved operating margins of 28.1%.

For the first nine months of FY25, JB Pharma achieved revenue of INR 2,969 crore, a 13% rise from INR 2,622 crore in the same period last year. Operating EBITDA also grew by 16% to INR 846 crore, with profit after tax increasing to INR 514 crore, a 20% jump.

Noteworthy growth in the domestic formulations business, which generated INR 566 crore in Q3 FY25 (22% growth), contributed significantly to overall performance. The company's focus on chronic and acute segments, along with a well-defined strategy for growth in domestic and international markets, positions it favorably for continued success. The outlook remains positive with robust growth prospects anticipated in the CDMO segment and a strong pipeline for future international product launches.